Using a biomarker to guide low-dose rituximab in rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial aims to find out if a simple blood test (biomarker) can show whether a lower dose of rituximab will work for people with rheumatoid arthritis. If successful, it could help patients maintain good results with less medicine and fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have rheumatoid arthritis as diagnosed by a rheumatologist
- You have been taking standard-dose rituximab and your doctor says it works well for you
- If you take other arthritis pills (like methotrexate or leflunomide), your dose has been the same for at least 3 months
- If you take steroids (like prednisone), your dose is 10 mg or less per day and stable for at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a lower dose (200 mg) of rituximab given every 6 months is effective for maintaining control of rheumatoid arthritis. It is for people who are already on rituximab maintenance therapy and have low to moderate disease activity.
This study follows different groups of people—from those at high risk of developing rheumatoid arthritis to those recently diagnosed—to learn more about the disease. By joining, you help researchers understand who gets RA and why, which may lead to earlier detection and better care.
This trial tests a new drug called telitacicept for people with rheumatoid arthritis (RA) that hasn't improved after trying multiple treatments. It aims to see if the drug can reduce joint pain and swelling when other medications have failed.
This trial tests a medical device to help people with rheumatoid arthritis stay in remission while on biologic therapy. The goal is to see if the device can prevent flares and maintain disease control.
This trial tests a new medicine called CLN-978, given as an injection under the skin, to see if it can help people with active rheumatoid arthritis who haven't improved enough with other treatments. CLN-978 works by targeting a specific immune cell to reduce inflammation.
This trial tests a new medicine called VDJ001 for people with moderate to severe rheumatoid arthritis who are already taking methotrexate. The goal is to see if VDJ001 helps reduce joint pain and swelling better than a placebo.
Hear when a new Rheumatoid Arthritis (RA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.